

Translation

Chugai to Establish the Organization Specializing in Early Clinical Development

- Aiming to Acquire the World's Top-level Quality and Speed Development Capabilities -

January 28, 2015 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; Chairman and CEO: Osamu Nagayama (hereafter "Chugai")] announced today that it will newly establish, Translational Clinical Research (hereafter "TCR") Div. as of April 1, 2015. The division specializes in early clinical development and work to solidify its functions in order to aim at rapidly acquiring Proof-of-Concept (PoC**) for projects under development that had been discovered and created in-house, and speedy shift to global development.

Chugai's mid-term management plan "ACCEL 15", sets "Acceleration of global development" as one of the top priority challenges. Newly establishing the TCR Div. as one of the measures to address those challenges will enable to build a development setup equipped with top-level quality and speed in the world, which would allow Chugai to obtain PoC at an early stage. Speedy acquisition of PoC is essential to submit an application at the earliest time and launch globally competitive products created in-house, which will contribute to the patients, and ultimately lead to maximizing product value.

Details of the establishment of this organization and organizational changes due to this are as follows:

- Establish Translational Clinical Research Div. as Chugai's first global organization
<Functions of the TCR Div.>
 - Assume the responsibility for translational clinical research areas for in-house projects, from the stage of the preclinical study to PoC (e.g., early acquisition of PoC, taking in of exploratory clinical capabilities in Europe and the U.S., etc.)
 - Head TCR functions in Japan-Europe-U.S. trilateral base (Chugai, Chugai Pharma U.S.A. and Chugai Pharma Europe)
- Establish the following depts. in the TCR Div.: TCR Science & Strategy Dept., TCR Study Management Dept., and TCR Operation Dept.
<Functions of each dept.>
 - TCR Science & Strategy Dept.: Responsible for the planning functions in early clinical development
 - TCR Study Management Dept.: Responsible for the implementing the clinical trial functions in early clinical development
 - TCR Operation Dept.: Responsible for functions relating to the overall management of early clinical development as well as division's administrative management

- Change the names of three depts. in the Clinical Development Div. as follows;

Current name	New name
Clinical Research Planning Dept.	Clinical Science & Strategy Dept.
Clinical Research Dept.	Clinical Study Management Dept.
Clinical Research Coordination Dept.	Clinical Operation Dept.

*Translational Clinical Research (TCR):

A clinical research ranging from preclinical research to PoC that clinically verifies the scientific concept that was developed through drug discovery operations in clinical setting

**Proof-of-Concept (PoC):

Demonstration that the therapeutic effects conceived in the research stage is effective in clinical setting

Under its business philosophy “Innovation all for the patients,” Chugai is committed to creating new value through offering innovative medical products and services, thereby contributing to healthcare and human health around the world.